Federal Grant Award Summary

Oregon Health & Science University received a $482,625 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective February 1, 2026 through January 31, 2028. The award supports research and development services focused on developing long-acting antiretroviral therapy (LA-ART) for sustained Simian Immunodeficiency Virus (SIV) suppression in rhesus macaques. The research aims to evaluate LA-ART as a therapeutic alternative to conventional daily antiretroviral regimens, addressing current limitations including high staffing costs, daily animal manipulation, and immune activation from carrier molecules associated with traditional daily injection protocols.

The primary deliverables include: (1) preclinical research demonstrating the efficacy of LA-ART in achieving durable viral suppression in SIV-infected rhesus macaques and characterizing its impact on latent viral reservoirs; and (2) comprehensive safety, tolerability, and pharmacokinetic assessments of repeated LA-ART dosing with evaluation of effects on anti-SIV immunity. Results will be compared against historical controls using conventional daily antiretroviral therapy. This work is designed to establish LA-ART as a viable preclinical platform for advancing next-generation antiretroviral strategies applicable to human immunodeficiency virus (HIV) cure research and treatment development.